Shares of Roche Holding AG (OTCMKTS:RHHBY – Get Rating) have been assigned an average recommendation of “Hold” from the twelve ratings firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $193.75.
A number of research analysts recently weighed in on RHHBY shares. Societe Generale raised Roche from a “hold” rating to a “buy” rating in a report on Monday, February 27th. Deutsche Bank Aktiengesellschaft lowered Roche from a “hold” rating to a “sell” rating in a report on Wednesday, January 18th. Jefferies Financial Group lowered Roche from a “buy” rating to a “hold” rating in a report on Wednesday, January 4th. Finally, Barclays lowered Roche from an “overweight” rating to an “equal weight” rating in a report on Monday, March 27th.
Institutional Trading of Roche
Several institutional investors and hedge funds have recently made changes to their positions in RHHBY. Thomas White International Ltd. lifted its position in shares of Roche by 5.0% in the first quarter. Thomas White International Ltd. now owns 38,072 shares of the company’s stock valued at $1,895,000 after acquiring an additional 1,810 shares in the last quarter. SVB Wealth LLC lifted its position in Roche by 101.3% during the first quarter. SVB Wealth LLC now owns 34,152 shares of the company’s stock worth $1,687,000 after buying an additional 17,188 shares during the period. Captrust Financial Advisors lifted its position in Roche by 21.5% during the first quarter. Captrust Financial Advisors now owns 40,357 shares of the company’s stock worth $1,998,000 after buying an additional 7,150 shares during the period. Sky Investment Group LLC lifted its position in Roche by 2.7% during the third quarter. Sky Investment Group LLC now owns 54,606 shares of the company’s stock worth $2,218,000 after buying an additional 1,450 shares during the period. Finally, Vigilant Capital Management LLC lifted its position in Roche by 455.6% during the third quarter. Vigilant Capital Management LLC now owns 2,439 shares of the company’s stock worth $99,000 after buying an additional 2,000 shares during the period. 0.28% of the stock is currently owned by hedge funds and other institutional investors.
Roche Trading Up 0.2 %
Roche Increases Dividend
The business also recently disclosed a dividend, which was paid on Monday, March 27th. Stockholders of record on Friday, March 17th were given a $0.8068 dividend. This is an increase from Roche’s previous dividend of $0.79. This represents a dividend yield of 2.22%. The ex-dividend date of this dividend was Thursday, March 16th.
Roche Company Profile
Roche Holding AG is a research healthcare company. It operates through the Pharmaceuticals and Diagnostics segments. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care.
Read More
- Get a free copy of the StockNews.com research report on Roche (RHHBY)
- Starbucks Stock Becomes a Value Play
- Kraft Heinz Recovery Gains Momentum
- Here’s Why AMD’s Weak Guidance Is A Blessing In Disguise
- BP Shares Sold Off After Earnings: Here Is What Upset Markets
- Will Forced Divesture Of Grail Boost Illumina Shareholder Value?
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
